Pepdexpepdex
Stack
№ 049

DNSP-11

A compound studied to protect the brain cells lost in Parkinson's. An 11-amino-acid peptide from the proGDNF domain (the prodomain of glial cell line-derived neurotrophic factor, GDNF), also called Dopamine Neuron Stimulating Peptide-11. Pre-clinical neuroprotection for dopaminergic neurons in Parkinson's models.

Nootropic
Evidence: Anecdotal

DNSP-11: A compound studied to protect the brain cells lost in Parkinson's. An 11-amino-acid peptide from the proGDNF domain (the prodomain of glial cell line-derived neurotrophic factor, GDNF), also called Dopamine Neuron Stimulating Peptide-11. Pre-clinical neuroprotection for dopaminergic neurons in Parkinson's models. DNSP-11 is a tiny peptide derived from the precursor of dopamine.

FDA ⓘ
Not approved
WADA
Not banned
Typical dose
No standardized human protocol
Half-life ⓘ
Short (minutes)
Route ⓘ
Subcutaneous (intra-cranial in animal models)
Schedule
Daily in animal protocols
In plain English

DNSP-11 is a tiny peptide derived from the precursor of dopamine. It protects dopaminergic neurons in Parkinson's animal models. Pre-clinical research only, there is no human protocol, and dosing community vendors sell does not match clinical trial material.

Status & legalityWhat do these mean? →
Natty? ⓘ
Not natty
FDA ⓘ
Not approved

Not FDA approved. Pre-clinical.

Compounding ⓘ
Not classified

Not formally categorized in the FDA bulks lists.

WADA ⓘ
Not listed
Prescribed ⓘ

Not prescribed in conventional medicine.

Who it's for

  • →Researchers studying Parkinson's disease pathways
  • →Neurodegeneration research contexts
  • →Educational reference, limited human data

What to expect

  1. Week 1

    Subtle. No published human user-reports of acute effect.

  2. Week 4

    Animal-model neuroprotection markers shift here.

  3. Week 8

    No long term human data exists.

Looking at DNSP-11? Your next 3 steps

  1. 1Work out your syringe units

    Vial size + BAC water turns into the exact units to draw for DNSP-11.

    Open calculator →
  2. 2See what to stack & monitor

    The companion supplements and the bloodwork worth tracking on this kind of protocol.

    Bloodwork guide →
  3. 3Save it & ask the Coach

    A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.

    Create free account →

How it works (mechanism)

11-amino-acid peptide from the proGDNF domain (the prodomain of glial cell line-derived neurotrophic factor, GDNF). Pre-clinical neuroprotection via direct neurotrophic action on dopaminergic neurons.

Dosing protocol

Members only

Stacks well with

Members only

Side effects

01Limited human safety data
02Theoretical effects on dopaminergic signaling
03Injection-site irritation

When NOT to use

  • ⚠Active psychiatric medication regimen affecting dopamine
  • ⚠Pregnancy / nursing
  • ⚠Anyone risk-averse to pre-clinical compounds

Common mistakes

  • • Treating it as Parkinson's treatment (it's pre-clinical research)
  • • Stacking it with dopamine agonists
  • • Long cycles without safety data

What it actually is

DNSP-11 is an 11-amino-acid peptide cut from the prodomain of GDNF, a growth factor that supports the dopamine neurons lost in Parkinson's disease. The interesting part is that the prodomain was assumed to be inert packaging, and this fragment turned out to have activity of its own. It is preclinical: eight indexed records, zero human trials, and no human dosing protocol.

GDNF is made as a larger precursor which is cut to release the active growth factor, and the leftover prodomain was long treated as a by-product. DNSP-11 comes from that region and, in animal models, protects and restores function in dopaminergic neurons — the cells that die in Parkinson's. The early animal work delivered it directly into the midbrain, and later animal studies used intranasal administration. Neither is subcutaneous injection, which is how it is sold — so the route mismatch is specifically with injection under the skin, not with every non-intracranial route.

Forms, and which is which

Intracranial delivery (research)The route the research used

Animal models deliver it directly into brain tissue. This is how the published neuroprotection work was done.

Verdict: The studied route, and not one available to anyone.

Subcutaneous injectionHow community use happens

The animal work used intranigral and later intranasal delivery. Whether a subcutaneous dose reaches the target region is unknown.

Verdict: The one route the animal work did not use.

IntranasalA studied non-invasive route

Intranasal delivery has been examined for this compound as a way to reach the brain without intracranial administration.

Verdict: More plausible than subcutaneous injection, and still early.

Established Parkinson's treatmentActually treating Parkinson's

Levodopa and the other approved therapies have decades of randomised evidence.

Verdict: The comparison anyone with a diagnosis should make first.

What it is claimed to do, graded

Protects and restores dopamine neuron functionLimited

Demonstrated in animal models including a 2010 PLoS One paper and 2014 work on dopamine neuron function. Real preclinical findings, delivered directly to brain tissue.

Treats Parkinson's disease in humansNone shown

Zero human trials. Grade F on the site's own ladder.

Reaches the brain when injected subcutaneouslyNone shown

The assumption the entire community use rests on, and it has never been tested.

Is safeNone shown

No human safety data at any dose. A compound that alters dopaminergic signalling has obvious potential for psychiatric and movement effects that nobody has characterised.

Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.

Pros and cons

Pros
  • • Genuinely interesting science — an active peptide found in a region assumed to be inert
  • • Published in reputable journals with consistent animal findings
  • • Targets a real and devastating unmet need
Cons
  • • Zero human trials — grade F on the site's own ladder
  • • The animal work used intranigral and intranasal delivery; subcutaneous injection is a different proposition
  • • No human dosing protocol exists, so any dose offered was invented
  • • Effects on dopaminergic signalling are unstudied in people and could plausibly cause psychiatric or movement problems
  • • Marketed to people with a serious neurological diagnosis

When to stop

  • • Any change in movement symptoms, in either direction
  • • Any mood, psychiatric or impulse-control change
  • • Injection-site reaction that spreads
  • • Honestly: before starting, if you have a Parkinson's diagnosis — discuss it with your neurologist

Interactions

Dopaminergic medication (levodopa, agonists)Avoid

A compound acting on dopamine neurons alongside dopaminergic drugs, with no interaction data and a diagnosis that needs careful titration.

AntipsychoticsAvoid

Both act on dopaminergic systems, in ways that have not been characterised together. Listed as a caution to take seriously rather than a demonstrated antagonism.

MAO-B inhibitorsMonitor

Used in Parkinson's, and there is no interaction data.

Delaying or replacing established treatmentAvoid

The most important line here. Parkinson's has treatments with real evidence, and this has none.

Nothing well characterisedCaution

There is no human interaction literature for this compound.

Is this for you?

Probably worth reading further if
  • • Laboratory research. There is no human context for this compound
Skip it if
  • • You have Parkinson's disease and are considering this alongside or instead of treatment — talk to your neurologist
  • • You take dopaminergic medication or antipsychotics
  • • You are pregnant or nursing
  • • You expect subcutaneous injection to reproduce what intranigral or intranasal delivery did in rats

The one number

0 human trials; the animal work used intranigral and intranasal delivery, not subcutaneous injection
Pepdex evidence index — counts are indexed PubMed records, not deduplicated trials; PubMed query for DNSP-11

Sources for the claims above

Free, no account needed

New to DNSP-11? Grab the starter checklist.

Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.

No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.

AI Coach, live sample
Member answer
is 250mcg of bpc enough for a knee injury?
For a knee, is the standard working dose and a solid place to start. The trick with BPC is consistency, give it weeks, not days. , run it , and don't drop below , results tend to fall off under that line. If nothing's moved by week 3, that's when earns its place.
how much bac water for a 10mg reta vial?
is the standard play for a 10 mg reta vial. That gives you , clean unit math across the whole titration: on a 100-unit insulin syringe. Run instead if you want fewer, more concentrated shots. Most people titrate up over , and that mix keeps the numbers cleanest.
what should i track on bloodwork for tirzepatide?
Lipid panel, ALT/AST (liver enzymes), and an A1C, baseline before you start then every 3 months. If you've got metabolic-syndrome history, add fasting glucose and insulin so you can actually watch insulin sensitivity improve. You don't need a big hormone panel for a GLP-1.

Numbers redacted in this preview. Members get the full answer, on their own stack.

Ask the Coach anything about DNSP-11 or your own stack. This is it working.

Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.

Unlock the full Coach, from $4.99/week →

Frequently asked

What is DNSP-11?+
DNSP-11 is a tiny peptide derived from the precursor of dopamine. It protects dopaminergic neurons in Parkinson's animal models. Pre-clinical research only, there is no human protocol, and dosing community vendors sell does not match clinical trial material.
Is DNSP-11 FDA approved?+
Not FDA approved. Pre-clinical.
Is DNSP-11 legal?+
DNSP-11 is not FDA-approved, so there is no approved prescription version. Most supply is sold as "research only" by peptide vendors. A compounding pharmacy may only use substances the FDA permits for compounding, and many research peptides are not permitted — do not assume a compounded prescription is available. Possession is generally not criminalized but distribution without authorization may be. Verify local laws.
Is DNSP-11 banned by WADA?+
DNSP-11 is not currently on the WADA prohibited list.
Are you still natty after taking DNSP-11?+
No. DNSP-11 is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe DNSP-11?+
Not prescribed in conventional medicine.
What's the typical dose of DNSP-11?+
Dosing depends on your goal, experience, and tolerance. The full DNSP-11 protocol (dose, frequency, and how to titrate) is in the members section on the entry page.
What are the side effects of DNSP-11?+
Common side effects include: Limited human safety data; Theoretical effects on dopaminergic signaling; Injection-site irritation. Less common effects and full safety details are on the entry page.
How long until DNSP-11 starts working?+
Subtle. No published human user-reports of acute effect.
What can you stack with DNSP-11?+
DNSP-11 is commonly combined with complementary compounds. The full stacking protocol (what to pair, dosing, and timing) is in the members section on the entry page.
Where do people get DNSP-11?+
Pepdex does not sell, ship, or recommend suppliers. DNSP-11 is not FDA-approved; prescription versions require licensed clinical care, and "research only" markets carry real legal and quality risks. /coa explains how to verify a Certificate of Analysis and /guides/scam-vendor-spotting covers the red flags.

Common questions about DNSP-11

Tracked alongside DNSP-11

Same goal, different aisle — each graded on its own evidence in the Pepdex catalog.

Semax →
the injectable-nootropic neighbour in the same threads
Noopept →
the oral comparison people reach for first
Choline →
the stack partner half these protocols assume
L-tyrosine →
the depleted precursor behind most focus complaints

More in Nootropic

№ 034
Oxytocin

The 'bonding hormone' you make naturally. Synthetic oxytocin is FDA-approved for labor; off-label use covers social, anxiety, and intimacy contexts.

№ 048
Cerebrolysin

A brain-recovery drug used abroad for stroke, head injury, and Alzheimer's. A porcine brain-derived peptide complex used clinically in 50+ countries (Russia, China, Mexico, EU) for stroke recovery, TBI, and Alzheimer's. It's a mixture of low-molecular-weight peptides, not a single compound.

№ 031
Semax

For alertness and focus. A Russian-origin nootropic peptide on the alert/focus end of the spectrum that pairs with Selank for a balanced cognitive stack.

№ 042
Dihexa

A brain compound aimed at building new connections between neurons. An angiotensin IV analog with strong synaptogenic effect in animal models, often-cited as 'BDNF on steroids.' Very limited human data.